No Data
No Data
Keros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical Trials
Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Keros Therapeutics (KROS)
HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price target.
Buy Rating Reaffirmed for Keros Therapeutics as KER-050 Advances Towards Phase 3 for MDS Treatment
Analysts' Top Healthcare Picks: Ascendis Pharma (ASND), Keros Therapeutics (KROS)
Buy Rating Affirmed for Keros Therapeutics: Promising Pipeline and Strong Financial Health
No Data